

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
Kenneth Brasel et al.

Docket No.: 2836-D

Group Art Unit: 1644

Serial No: 09/448,378

Examiner: F. VanderVegt

Filed: November 23, 1999

For: DENDRITIC CELL STIMULATORY
FACTOR

RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed April 14, 2000, in which the Examiner restricted claims 1-19 of the above-captioned patent application into nine (9) different groups of inventions, Applicants hereby elect, without traverse, Group II for examination.

Group II was defined as claims 1, 2, 6 and 7, drawn to a method of enhancing an immune response to treat cancer. However, Applicants note that the application was filed with additional claims 20 and 21, which Applicants presume are included in the elected invention of Group II. In addition, Applicants offer the following amendments.

AMENDMENTS

In the specification:

At page 4, line 36, please insert the following text after the period:

--In particular, flt3-ligand for use in the invention includes, but is not limited to, murine and human flt-3 ligand. Particularly preferred forms of flt-3 ligand are biologically active, soluble forms of flt-3 ligand. The flt-3 ligand can be a soluble fusion form of the protein. For example, human flt-3 ligand for use in the invention can comprise an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:2 and amino acids 28 to Yaa of SEQ ID NO:1, wherein Xaa is an amino acid from